Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ranibizumab on Malignant Conjunctival Neoplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study~* Age \> 21 years~* Tumors whose treatment with standard therapy would cause significant visual morbidity~* Diagnosis of biopsy proven malignant conjunctival neoplasia and are~* Recurrent disease~* Multi-focal disease~* Diffuse disease~Exclusion Criteria:~* Extension of tumor into eye or orbit.~* Regional spread or metastatic disease~* Pregnancy (positive pregnancy test) or lactation.~* Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.~* Current infection or inflammation in either eye~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~* Participation in another simultaneous medical investigation or trial

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subconjunctival ranibizumab (Type: EXPERIMENTAL): Patients will receive subconjunctival ranibizumab every 2-4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).